D-erythro-MAPP
Based on 1 publication(s) in Google Scholar
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.65%
- CAS 番号: 143492-38-0
- 分子式: C23H39NO2
- 分子量:361.56
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-14113
2-Acetyl-4-tetrahydroxybutyl imidazoleS1P Lyase Inhibitor -
HY-116535
D-threo-PPMP hydrochlorideGlcCer Synthase Inhibitor -
HY-124955
proTAMEAPC Inhibitor -
HY-D0952
Acridine Orange baseFluorescent Dye -
HY-148292
C16-Sphingosine-1-phosphateEDG/S1P Receptor Ligand -
HY-165064
C2 L-Erythro ceramide (d18:1/2:0)Sphingolipid -
HY-116703
L-erythro-DihydrosphingosineEster Product -
HY-156208
C2 Adamantanyl galactosylceramide (d18:1/2:0)GlcCer Inhibitor -
HY-158940
N-Glycine 3'-sulfo galactosylsphingosineLyso-sulfatide (bovine) ammonium Analog
MedChemExpress（MCE）の使用を引用している文献 D-erythro-MAPP
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
1 μM
Compound: D-e-MAPP
|
Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis
Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis
|
[PMID: 23312611] |
| HL-60 | IC50 |
1 μM
Compound: D-e-MAPP
|
Inhibition of aCDase expressed in human HL60 cell extract
Inhibition of aCDase expressed in human HL60 cell extract
|
[PMID: 22989912] |
| MCF7 | IC50 |
30 μM
Compound: D-e-MAPP
|
Antiproliferative activity against human MCF7 cells after 48 hrs
Antiproliferative activity against human MCF7 cells after 48 hrs
|
[PMID: 17869115] |
体外実験
D-erythro-MAPP (D-e-MAPP) reduces the viability of MCF-7 cells in a dose-dependent manner with IC50 value of 4.4 μM, and 15.6 μM, respectively[1].
D-erythro-MAPP (D-e-MAPP) induces G0/G1 arrest in cell cycle progression resulting in growth suppression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:Human breast cancer MCF-7 cells.
-
Concentration:24 h.
-
Incubation Time:3.13-100 μM.
-
Result:Inhibited cell viability.
化学情報
-
CAS 番号 143492-38-0
-
性状 Solid
-
分子量 361.56
-
分子式 C23H39NO2
-
Color White to off-white
-
SMILES
O[C@@H](C1=CC=CC=C1)[C@@H](C)NC(CCCCCCCCCCCCC)=O
-
別名
D-e-MAPP
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism. [Abstract]2024 Sep:63:17-33. PMID: 37865189
溶剤 & 溶解度
体外:
DMF : ≥ 20 mg/mL (55.32 mM)
Ethanol : ≥ 20 mg/mL (55.32 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Hüseyin İzgördü, et al. Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. Cytotechnology. 2020 Dec;72(6):907-919. [Content Brief]
[2]. A Bielawska, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem. 1996 May 24;271(21):12646-54. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / Ethanol | 1 mM | 2.7658 mL | 13.8290 mL | 27.6579 mL | 69.1448 mL |
| 5 mM | 0.5532 mL | 2.7658 mL | 5.5316 mL | 13.8290 mL | |
| 10 mM | 0.2766 mL | 1.3829 mL | 2.7658 mL | 6.9145 mL | |
| 15 mM | 0.1844 mL | 0.9219 mL | 1.8439 mL | 4.6097 mL | |
| 20 mM | 0.1383 mL | 0.6914 mL | 1.3829 mL | 3.4572 mL | |
| 25 mM | 0.1106 mL | 0.5532 mL | 1.1063 mL | 2.7658 mL | |
| 30 mM | 0.0922 mL | 0.4610 mL | 0.9219 mL | 2.3048 mL | |
| 40 mM | 0.0691 mL | 0.3457 mL | 0.6914 mL | 1.7286 mL | |
| 50 mM | 0.0553 mL | 0.2766 mL | 0.5532 mL | 1.3829 mL |
D-erythro-MAPP 関連分類
HY-137422 関連分類
Powered by Bioz